Omnicell Is Maintained at Equal-Weight by Wells Fargo
Omnicell Analyst Ratings
Craig-Hallum Maintains Omnicell(OMCL.US) With Buy Rating
Craig-Hallum Sticks to Its Buy Rating for Omnicell (OMCL)
Wells Fargo Maintains Omnicell(OMCL.US) With Hold Rating, Maintains Target Price $40
J.P. Morgan Maintains Omnicell(OMCL.US) With Hold Rating, Cuts Target Price to $36
JP Morgan Maintains Neutral on Omnicell, Lowers Price Target to $36
Omnicell Analyst Ratings
Craig-Hallum Maintains Omnicell(OMCL.US) With Buy Rating
Craig-Hallum Remains a Buy on Omnicell (OMCL)
BofA Securities Maintains Omnicell(OMCL.US) With Hold Rating, Cuts Target Price to $38
Wells Fargo Maintains Omnicell(OMCL.US) With Hold Rating, Maintains Target Price $40
Piper Sandler Maintains Omnicell(OMCL.US) With Buy Rating, Maintains Target Price $69
Analysts Are Bullish on Top Healthcare Stocks: Penumbra (PEN), Omnicell (OMCL)
Craig-Hallum Maintains Omnicell(OMCL.US) With Buy Rating, Announces Target Price $64
A Quick Look at Today's Ratings for Omnicell(OMCL.US), With a Forecast Between $40 to $62
Craig-Hallum Keeps Their Buy Rating on Omnicell (OMCL)
Omnicell Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Iovance Biotherapeutics (IOVA) and Omnicell (OMCL)
Benchmark Co. Maintains Omnicell(OMCL.US) With Buy Rating, Maintains Target Price $62